3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now

The article argues that AT&T, Pfizer and Zoetis offer attractive dividend income at low valuations as rising rates and bond yields pressure dividend stocks. AT&T is down about 16% this year, trades near $21 at 11 times earnings and yields 5.3%; Pfizer is around $30 with a 10 forward P/E and 5.8% yield; Zoetis has fallen 37% this year, trades below $80 at 13 times earnings and yields about 2.6%. Zoetis revenue rose 1% to $4.7 billion in the first six months of the year, and the article cites 12 potential blockbuster products in its pipeline and a payout ratio of about 34%.

Analysis

The common risk is duration, not simply whether these businesses are “quality”: if bond yields stay elevated, income-oriented buyers may demand cheaper entry prices, limiting near-term multiple recovery. A falling share price raises a quoted yield but does not itself improve dividend coverage.

AT&T: the Starlink threat is more likely a gradual competitive and pricing risk than an immediate nationwide substitution; spectrum, service economics and regulatory execution matter. Near term, the key test is whether subscriber economics and free-cash-flow conversion support the payout, not the low trailing P/E. Over 6–18 months, sustained pricing pressure would undermine the “cheap yield” case.

Pfizer: a low forward multiple is only compelling if post-restructuring earnings estimates survive patent-expiry exposure and pipeline execution. The market may be discounting a longer earnings reset than the article allows; analyst forecasts are not evidence of a floor. Revisions to earnings and clinical/regulatory milestones matter more than the headline multiple.

Zoetis: the selloff may create value, but 1% revenue growth makes a low multiple potentially a growth reset, not a bargain. Pipeline candidates are options, not current revenue; launches, adoption and competitive substitution need validation. Contrarian point: none of the three is automatically mispriced just because its yield or P/E looks low. The article supplies no cash-flow, debt, consensus-revision or valuation-history detail, so conviction should remain conditional.

Key Decisions for Investors

• AT&T: consider only a small, staged income position after verifying recent free-cash-flow coverage of dividends and the direction of net debt. Reassess if coverage weakens, subscriber/pricing metrics deteriorate, or yields rise enough to keep telecom multiples under pressure.
• Pfizer: avoid buying solely on the stated forward P/E. Track earnings-estimate revisions, patent-expiry revenue exposure, restructuring savings and pipeline readouts over the next 1–3 months; add only if estimates stabilize without relying on unverified pipeline upside.
• Zoetis: keep on a watchlist rather than treating pipeline potential as a catalyst. Require evidence of improving organic growth, launch contribution or management guidance stabilization; continued weak growth or downward revisions would falsify the cheap-recovery thesis.
• Across the group, avoid a yield-chasing basket ahead of rate-sensitive macro catalysts. A sustained decline in bond yields could support valuation recovery; another leg higher in yields would challenge all three, with the weakest fundamental trend likely to underperform.